Wandstrat T L, Wolfe M
Robert C. Byrd Health Sciences Center, Charleston, WV 25304, USA.
Neonatal Netw. 1996 Oct;15(7):25-8.
Anemia of prematurity (AOP) affects almost all infants that are born prematurely. Excessive phlebotomy in the NICU setting has exacerbated this condition. Until recently, erythrocyte transfusion has been the only therapy for AOP. Recombinant human erythropoietin (rh-EPO) has been shown to be effective in reducing erythrocyte transfusions in premature infants with AOP. Various studies have utilized rh-EPO as a treatment modality or as prophylaxis for AOP. The results of these studies have shown that rb-EPO is a complementary strategy along with restriction of phlebotomy and less liberal transfusion policies, to decreasing the number of transfusions that an infant may need. Trials are necessary to document the cost-effectiveness of rh-EPO as well as its long term effects on the premature infant.
早产儿贫血（AOP）几乎影响所有早产出生的婴儿。新生儿重症监护病房（NICU）环境下过多的静脉采血加剧了这种情况。直到最近，红细胞输血一直是治疗AOP的唯一疗法。重组人促红细胞生成素（rh-EPO）已被证明在减少患有AOP的早产儿的红细胞输血方面有效。各种研究已将rh-EPO用作治疗方式或AOP的预防措施。这些研究的结果表明，rb-EPO是一种与限制静脉采血和不太宽松的输血政策相辅相成的策略，可减少婴儿可能需要的输血次数。有必要进行试验以证明rh-EPO的成本效益及其对早产儿的长期影响。
